Abstract
The pharmacodynamic effects of metronidazole on Trichomonas vaginalis have been poorly characterized. The present in vitro study was performed to characterize the relationship between killing of trichomonads and metronidazole exposure (metronidazole concentration and time of exposure). Five laboratory strains and five recent clinical isolates of T. vaginalis were studied. The minimum lethal concentrations (MLCs) of metronidazole for the strains ranged from 0.8 to 25 micrograms/ml under anaerobic conditions. Metronidazole exhibited concentration-dependent killing against T. vaginalis at concentrations ranging from 0.1 to > 10 times the MLC. The endpoint measurement, the kill rate constant, which was derived from the reduction in the logarithm of the colony count divided by exposure time, compared with the kill rate constant for the growth control was not affected by the time of assessment between 2 and 24 h. The kill rate constant-versus-metronidazole exposure curves were similar when concentration was expressed as a multiple of the MLC. There were no apparent differences between the clinical isolates and laboratory strains. These data suggest that peak metronidazole concentration and/or area under the plasma concentration-versus-time curve are the important pharmacodynamic parameters to be optimized.
Full Text
The Full Text of this article is available as a PDF (266.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Amon I., Amon K., Hüller H. Pharmacokinetics and therapeutic efficacy of metronidazole at different dosages. Int J Clin Pharmacol Biopharm. 1978 Aug;16(8):384–386. [PubMed] [Google Scholar]
- Jensen J. C., Gugler R. Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther. 1983 Oct;34(4):481–487. doi: 10.1038/clpt.1983.201. [DOI] [PubMed] [Google Scholar]
- Krieger J. N., Dickins C. S., Rein M. F. Use of a time-kill technique for susceptibility testing of Trichomonas vaginalis. Antimicrob Agents Chemother. 1985 Mar;27(3):332–336. doi: 10.1128/aac.27.3.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lossick J. G. Treatment of sexually transmitted vaginosis/vaginitis. Rev Infect Dis. 1990 Jul-Aug;12 (Suppl 6):S665–S681. doi: 10.1093/clinids/12.supplement_6.s665. [DOI] [PubMed] [Google Scholar]
- Lyng J., Christensen J. A double-blind study of the value of treatment with a single dose tinidazole of partners to females with trichomoniasis. Acta Obstet Gynecol Scand. 1981;60(2):199–201. [PubMed] [Google Scholar]
- Meingassner J. G., Mieth H., Czok R., Lindmark D. G., Müller M. Assay conditions and the demonstration of nitroimidazole resistance in Tritrichomonas foetus. Antimicrob Agents Chemother. 1978 Jan;13(1):1–3. doi: 10.1128/aac.13.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Meingassner J. G., Thurner J. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother. 1979 Feb;15(2):254–257. doi: 10.1128/aac.15.2.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Müller M., Lossick J. G., Gorrell T. E. In vitro susceptibility of Trichomonas vaginalis to metronidazole and treatment outcome in vaginal trichomoniasis. Sex Transm Dis. 1988 Jan-Mar;15(1):17–24. doi: 10.1097/00007435-198801000-00004. [DOI] [PubMed] [Google Scholar]
- Rein M. F. Current therapy of vulvovaginitis. Sex Transm Dis. 1981 Oct-Dec;8(4 Suppl):316–320. [PubMed] [Google Scholar]